维甲类化合物R8605的抗化学致癌和抗促癌作用

本实验根据癌发生的多阶段理论,利用化学性诱发的小鼠二阶段皮肤乳头瘤模型。研究了维甲类化合物R8605的抗化学致癌和抗促癌作用。结果表明,R8605(50mg/kg和25mg/kg,口服)能明显抑制由二甲基苯蒽(DMBA)和巴豆油诱发的小鼠皮肤乳头瘤生成,并表现出较强的抗促癌作用;另外,R8605还能明显抑制巴豆油对小鼠皮肤表皮鸟氨酸脱羧酶(ODC)活性的诱导。R8605较大剂量(100mg/kg,口服)时,也能抑制巴豆油诱发的小鼠耳部肿胀。R8605的抗促癌作用可能与其抑制ODC活性及抗炎作用有一定的关系。

Anti-carcinogenic and Anti-promoting Effects of Retinoid R8605

R8605 belongs to the third generation retinoid and was found during the systematic screening of cancer chemopreventive agents in our institute. Based on the theory of multistage carcinogenesis, the anti-carcinogenic and anti-promoting effects of R8605 as well as its possible anti-promoting mechanisms were studied. Experiments proved that R8605 (50 mg/kg and 25 mg/kg, i.g.) significantly inhibited the growth of skin papillomas induced by 7, 12-dime-thylbenza]anthracene and croton oil in mice and exhibited a potent anti-pro-moting action. In addition, R8605 (50 mg/kg and 25 mg/kg, i.g.) strongly inhibited the induction of ornithine decarboxylase (ODC) activity of mouse skin epidermis by croton oil.At a dose of 100 mg/kg of R8605 (i.g.) croton oil-induced ear edema in micewas suppressed. These results suggest that the anti-promoting effect of R8605 might be associated with its anti-inflammatory action and it's inhibitory effect on ODC activity.